The war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo ...

With an expanded recommendation from the Center for Disease Control and Prevention (CDC)’s Advisory Committee on Immunization ...

By squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. | Despite ...

Genentech, the biotech unit of Swiss major Roche, has been marketing lung cancer drugs for nearly two decades, starting with ...

Eli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. | Lilly's Alzheimer ...

While Regeneron may have lost its latest bid to block the launch of Amgen’s Eylea biosimilar Pavblu, the New York-based ...

Legend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese ...

The groups behind the letter alleged that Novo Nordisk’s plant purchases could hinder not only the Danish drugmaker’s chief ...

While it’s a win for Pfizer over GSK and its RSV vaccine Arexvy, which is approved for those 50 and older, it’s difficult to ...

Initially, the U.S. and European groups kept vestiges of their old identities, operating as ICR Westwicke and ICR Consilium.

There’s change at the top of Ogilvy Health. Kim Johnson is leaving to pursue new opportunities after three years as CEO, ...

There’s no denying it: the radiopharmaceuticals boom is here to stay. | Telix on Tuesday unveiled the spin-off of Rhine ...